We found a very high level of c-MYC in the vector + nanocage-treated group (Figures 3A–C), a moderate level of c-MYC expression in the 3× IC50-treated tumor group (Figures 3D–F), and complete inhibition of the c-MYC expression in the 6× IC50 and 9× IC50 3′UTRMYC1-18-treated groups (Figures 3G–J,L), quantified in Figure 3O. The gene discussed is MYC; the disease is neoplasm.